Appendix 4C - Quarterly Cashflow report
Starpharma today released its Appendix 4C - Quarterly Cashflow report for the period ended 30 June 2012.
Starpharma presenting at Nomura Biotech Investment conference
• CEO Dr Jackie Fairley presenting at the Nomura Biotech Conference for institutional investors in Sydney, 24th July 2012.
• Presentation to include update on the rapidly advancing VivaGel® Bacterial Vaginosis Program, and advancements in Drug Delivery and Agrochemicals Programs.
Drug Delivery Update: Starpharma reports rapid advancement of drug delivery program
Starpharma today provided an update on the developments within its substantial drug delivery program.
Key Points:
> Dendrimer-docetaxel program advancing rapidly; clinical trial expected to commence in 2013
> Successful application of dendrimers to a number of important classes of drugs including small molecules, antibodies and proteins
> Analysis shows Starpharma’s dendrimers applicable to more than 50% of top-selling pharmaceuticals - highlighting versatility and potential to develop improved formulations